Abstract It is well known that immune cells including macrophage within the tumor microenvironment play an essential role in tumor progression. Here, we studied how NFATc2 regulates macrophage properties in lung adenocarcinoma. Positive relationships were found between NFATc2 and genes associated with hypoxia and glycolysis in lung adenocarcinoma from the TCGA dataset. NFATc2 enhanced cell migration and lactate levels in lung adenocarcinoma cells. According to single-cell sequence data, NFATc2 is closely associated with infiltrating immune cells and is related to macrophage polarization. NFATc2 promotes M2 polarization in macrophages. As a transcription factor, NFATc2 binds to the USP17 promoter region. Furthermore, the NFATc2 inhibitor suppressed M2 polarization induced by USP17. In conclusion, NFATc2 promotes lactate levels and M2 polarization of macrophages by transcriptionally regulating USP17 in lung adenocarcinoma.

A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) has previously shown its preliminary efficacy in ST elevation myocardial infarction (STEMI) patients. This study was designed as a pivotal postmarketing trial to compare its efficacy and safety with rrecombinant human tissue-type plasminogen activator alteplase (rt-PA) in Chinese patients with STEMI. In this multicenter, randomized, open-label, non-inferiority trial, patients with acute STEMI were randomly assigned (1:1) to receive an intravenous bolus of 16 mg rhTNK-tPA or an intravenous bolus of 8 mg rt-PA followed by an infusion of 42 mg in 90 min. The primary endpoint was recanalization defined by thrombolysis in myocardial infarction (TIMI) flow grade 2 or 3. The secondary endpoint was clinically justified recanalization. Other endpoints included 30-day major adverse cardiovascular and cerebrovascular events (MACCEs) and safety endpoints. From July 2016 to September 2019, 767 eligible patients were randomly assigned to receive rhTNK-tPA ( n = 384) or rt-PA ( n = 383). Among them, 369 patients had coronary angiography data on TIMI flow, and 711 patients had data on clinically justified recanalization. Both used a -15% difference as the non-inferiority efficacy margin. In comparison to rt-PA, both the proportion of patients with TIMI grade 2 or 3 flow (78.3% [148/189] vs. 81.7% [147/180]; differences: -3.4%; 95% confidence interval [CI]: -11.5%, 4.8%) and clinically justified recanalization (85.4% [305/357] vs. 85.9% [304/354]; difference: -0.5%; 95% CI: -5.6%, 4.7%) in the rhTNK-tPA group were non-inferior. The occurrence of 30-day MACCEs (10.2% [39/384] vs. 11.0% [42/383]; hazard ratio: 0.96; 95% CI: 0.61, 1.50) did not differ significantly between groups. No safety outcomes significantly differed between groups. rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI. www.ClinicalTrials.gov (No. NCT02835534).

Subsequent to the publication of the above article, a concerned reader drew to our attention that the flow cytometric plots shown in Fig.2 had previously appeared in another article published in the journal OncologyReports [Huang G, TangB, TangK, Dong X, Deng J, Liao L, Liao Z, YangH and HeS:Isoquercitrin inhibits the progression of liver cancer invivo and invitro via the MAPK signalling pathway. OncolRep 31:2377‑2384, 2014], suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source. Given the errors that were identified in the compilation of Fig.2 in this article, and the fact that all the data in this figure had been re‑used from a previously published source, the Editor of Oncology Reports has decided that this article should be retracted from the publication owing to a lack of overall confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience that might result from the retraction of this article. [Oncology Reports33: 840‑848, 2015; DOI: 10.3892/or.2014.3626].

The study employed simple differential blood count assessing clinical prognosis index at diagnosis of DLBCL patients. Each patient’s prognostic performance status was computed using absolute neutrophils/absolute lymphocytes(ANC/ALC), absolute lymphocytes/absolute monocyte (ALC/AMC), and absolute platelet/absolute lymphocytes APC/ALC) respectively, and then compared to preexisting parameters IPI, ECOG-PS, KI-67% protein expression, LDH, gender, bone marrow infiltration, and tumor location using ROC curves to determine the sensitivity and specificity threshold of each CBC performance index and survival analysis to estimate 5-year PFS and OS. The study showed that NLR compared to LDH at NLR ≥ 3.50 correlates to an increase in LDH >230UI/L, ECOG-PS score 2-4, increase in nodal tumor location, and elevation in cell proliferation at ki-67% protein expression (≥20%) at diagnosis exhibit poor prognosis to R-CHOP chemotherapy. Our results also demonstrated that LMR≤2.50 was associated with ECOG-PS score 2-4, increased number of extranodal tumor locations, in comparison with gender female participants had high sensitivity 60%, also low score LMR≤ 2.50 correspond to IPI score 3-5 among DLBCL patients. Our results further revealed that Pretreatment PLR≥150 at diagnosis correlates with LDH>230UI/L, and an ECOG-PS score of 2-4 in DLBCL patients.Conclusion: This study confirmed that pretreatment differential blood index NLR, LMR, and PLR are strongly associated with clinicopathological characteristics and provide important clinical prognostics in the early detection of DLBCL to the rituximab combined regimen.

At present, the feature extraction method of radiology is mainly based on static tomography images at a certain time. However, the occurrence and development of disease is a dynamic process, and the information contained in static images is not enough to fully evaluate the patient’s condition. Therefore, in this study, we propose a new dynamic radiomics feature extraction workflow that uses time-related tomographic images of the same patient to extract static features at different times, which are then quantified as new dynamic features for diagnosis or prognostic evaluation. We first define the concept and mathematical paradigm of dynamic radiomics and propose three types of construction methods for dynamic features to describe static features over time from different perspectives. Three different clinical questions were used to compare the performance of dynamic features with conventional static features in predicting different clinical questions. The results of all experimental cohorts show that the newly proposed dynamic features can achieve higher sensitivity, specificity and accuracy than static features and have higher robustness. We also found that different dynamic features may be desired to address different clinical issues.

The online version contains supplementary material available at 10.1007/s13167-021-00261-2.